New hope for kids with tough leukemia: targeted drugs added to chemo

NCT ID NCT06390319

Recruiting now Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongside their usual treatment. The goal is to see if these combinations lead to better outcomes than standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIXED PHENOTYPE ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia mixed phenotype acute leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia T-cell non-Hodgkin lymphoma T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED PHENOTYPE ACUTE LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Novant Health Presbyterian Hemby Children's Hospital
RECRUITING

Charlotte, North Carolina, 28204, United States
Rady Children's Hospital
RECRUITING

San Diego, California, 92123, United States
Saint Francis Children's Hospital
RECRUITING

Tulsa, Oklahoma, 74136, United States
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.